Literature DB >> 22293790

[Regression grading in gastrointestinal tumors].

I Tischoff1, A Tannapfel.   

Abstract

Preoperative neoadjuvant chemoradiation therapy is a well-established and essential part of the interdisciplinary treatment of gastrointestinal tumors. Neoadjuvant treatment leads to regressive changes in tumors. To evaluate the histological tumor response different scoring systems describing regressive changes are used and known as tumor regression grading. Tumor regression grading is usually based on the presence of residual vital tumor cells in proportion to the total tumor size. Currently, no nationally or internationally accepted grading systems exist. In general, common guidelines should be used in the pathohistological diagnostics of tumors after neoadjuvant therapy. In particularly, the standard tumor grading will be replaced by tumor regression grading. Furthermore, tumors after neoadjuvant treatment are marked with the prefix "y" in the TNM classification.

Entities:  

Mesh:

Year:  2012        PMID: 22293790     DOI: 10.1007/s00292-011-1545-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  16 in total

Review 1.  [Update S3-guideline "colorectal cancer" 2008].

Authors:  W Schmiegel; A Reinacher-Schick; D Arnold; U Graeven; V Heinemann; R Porschen; J Riemann; C Rödel; R Sauer; M Wieser; W Schmitt; H-J Schmoll; T Seufferlein; I Kopp; C Pox
Journal:  Z Gastroenterol       Date:  2008-08       Impact factor: 2.000

2.  [The "recovery center" - structural requirements for the hospital of the future].

Authors:  W Mutschler
Journal:  Zentralbl Chir       Date:  2011-02-28       Impact factor: 0.942

3.  Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.

Authors:  L Rubbia-Brandt; E Giostra; C Brezault; A D Roth; A Andres; V Audard; P Sartoretti; B Dousset; P E Majno; O Soubrane; S Chaussade; G Mentha; B Terris
Journal:  Ann Oncol       Date:  2006-10-23       Impact factor: 32.976

4.  Histomorphological tumor regression grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score to use?

Authors:  R M Hermann; O Horstmann; F Haller; C Perske; H Christiansen; A Hille; H Schmidberger; L Füzesi
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

5.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

6.  Pathological features of rectal cancer after preoperative radiochemotherapy.

Authors:  O Dworak; L Keilholz; A Hoffmann
Journal:  Int J Colorectal Dis       Date:  1997       Impact factor: 2.571

Review 7.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

8.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

9.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

Authors:  Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

10.  Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.

Authors:  Romuald Le Scodan; Françoise Mornex; Christian Partensky; Catherine Mercier; Pierre-Jean Valette; Marc Ychou; Pascal Roy; Jean-Yves Scoazec
Journal:  Am J Clin Oncol       Date:  2008-12       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.